FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4253330277> ?p ?o ?g. }

• W4253330277 endingPage "2900" @default.
• W4253330277 startingPage "2900" @default.
• W4253330277 abstract "Abstract Abstract 2900 Increasing use of chemo-immunotherapy in CLL has raised concerns over the carcinogenic effect of FCR regimen. Fludarabine based regimen in relapsed CLL has been reported to be predisposed to a higher risk of other cancers as compared to healthy individual. However, an association between the CLL treatment and the development of other cancers is not evident in the frontline FCR setting. We retrospectively studied the frequency, characteristics, and clinical outcomes of second malignancy in patients with CLL who were treated with frontline FCR-based therapy at University of Texas, MD Anderson Cancer Center from 2004 to 2010. Patients who developed other malignancies after the initiation of FCR-based therapy were considered as patients with second cancer post CLL treatment (n=39). Patients who had history of other malignancies before the initiation of FCR-based therapy were considered as patients with prior malignancy history (n=90). Patients who neither have history of other cancers nor patients developed second cancer during the study period were assigned as patients without second cancer group (n=82). There were 24 patients (n=24) who experienced Richter's transformation post FCR-based therapy. The overall survival (OS) was measured from the initiation of CLL treatment until death from any causes or last follow-up. Progression-free survival (PFS) was measured from the initiation of CLL treatment until disease progression, relapse or death. Kaplan-Meier method was used to estimate outcomes in four groups. Cox-proportional hazard regression model was used to assess the association between patient characteristics and survival outcomes. Pre-treatment characteristics were similar among these groups except for chromosome abnormalities. Ten patients (44%) out of 24 patients with Richter's transformation had TP53 gene mutation (p <0.05). Ninety patients (38%) of 235 patients had prior malignancy history includes non-melanoma skin cancer (n=32, 36%), melanoma (n=12, 13%), prostate cancer (n=15, 17%), colon cancer (n=5, 6%), renal cancer (n=2, 2%) and follicular lymphoma (n=1, 1%). Among 145 patients without prior malignancy history, there were 39 patients (27%) who developed second cancer including other leukemia, and 24 patients (17%) who developed Richter's transformation after the FCR-based therapy. The median time from initiation of FCR-based therapy to the development of Richter' transformation was 13.53 months (range, 1.63 to 40.87). There was no patient with prior history of other malignancies had recurrent cancers during the study. Thirty nine patients who developed second cancer includes non-melanoma skin (n=10, 26%), melanoma (n=2, 5%), head and neck (n=1, 2.5), Merkel cell (n=1, 2.5%), prostate (n=6, 15%), breast (n=1, 2.5%), lung (n=2, 5%) renal (n=1, 2.5%), gastric (n=2, 5%), liver (n=1, 2.5%), Hodgkin (n=1, 2.5%), and therapy-related MDS-AML (n=11, 28%). The estimated median PFS in the whole cohort was 4.57 years (95% CI: 3.678 to 5.462). PFS in patients without second cancer was not reached (NR) compared to 3.31 years (95% CI: 2.178 to 3.542) in patients with second cancer post CLL treatment (p<0.05). PFS in patients with Richter's transformation was 1.02 years (95% CI: .625 to 1.415). The median follow up duration for all 235 patients was 3.29 years (range, 0.08–8.51 years) with total of 61 deaths. The median overall survival in either group of patients with prior malignancy history or in patients without second cancers were not reached (NR) compared with 3.81 years (95% CI: 2.231 to 5.389) in patients with second cancer (p < 0.05). OS in patients with Richter's transformation was 3.84 years (95% CI, 1.434 to 6.246) There were 8 patients (10%) who died among 82 patients without second cancer as compared to 20 patients (49%) who died among 39 patients with second cancer (p <0.05). Second cancers in patients with CLL treated with FCR regimen are significantly associated with inferior clinical outcomes. We observed the high incidence of skin cancer, prostate and Richter's transformation in patients with CLL who underwent treatment with frontline FCR-based therapy. Further studies are warranted to determine the association between FCR regimen and the development of second cancer, especially Richter's transformation. Disclosures: No relevant conflicts of interest to declare." @default.
• W4253330277 created "2022-05-12" @default.
• W4253330277 creator A5027575595 @default.
• W4253330277 creator A5029703058 @default.
• W4253330277 creator A5035354255 @default.
• W4253330277 creator A5046135731 @default.
• W4253330277 creator A5046837534 @default.
• W4253330277 creator A5081588858 @default.
• W4253330277 creator A5083223035 @default.
• W4253330277 date "2012-11-16" @default.
• W4253330277 modified "2023-09-27" @default.
• W4253330277 title "Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy." @default.
• W4253330277 doi "https://doi.org/10.1182/blood.v120.21.2900.2900" @default.
• W4253330277 hasPublicationYear "2012" @default.
• W4253330277 type Work @default.
• W4253330277 citedByCount "1" @default.
• W4253330277 countsByYear W42533302772020 @default.
• W4253330277 crossrefType "journal-article" @default.
• W4253330277 hasAuthorship W4253330277A5027575595 @default.
• W4253330277 hasAuthorship W4253330277A5029703058 @default.
• W4253330277 hasAuthorship W4253330277A5035354255 @default.
• W4253330277 hasAuthorship W4253330277A5046135731 @default.
• W4253330277 hasAuthorship W4253330277A5046837534 @default.
• W4253330277 hasAuthorship W4253330277A5081588858 @default.
• W4253330277 hasAuthorship W4253330277A5083223035 @default.
• W4253330277 hasConcept C121608353 @default.
• W4253330277 hasConcept C126322002 @default.
• W4253330277 hasConcept C143998085 @default.
• W4253330277 hasConcept C207103383 @default.
• W4253330277 hasConcept C2776694085 @default.
• W4253330277 hasConcept C2776755627 @default.
• W4253330277 hasConcept C2777938653 @default.
• W4253330277 hasConcept C2778461978 @default.
• W4253330277 hasConcept C2779263901 @default.
• W4253330277 hasConcept C2779399171 @default.
• W4253330277 hasConcept C2781413609 @default.
• W4253330277 hasConcept C44249647 @default.
• W4253330277 hasConcept C50382708 @default.
• W4253330277 hasConcept C71924100 @default.
• W4253330277 hasConceptScore W4253330277C121608353 @default.
• W4253330277 hasConceptScore W4253330277C126322002 @default.
• W4253330277 hasConceptScore W4253330277C143998085 @default.
• W4253330277 hasConceptScore W4253330277C207103383 @default.
• W4253330277 hasConceptScore W4253330277C2776694085 @default.
• W4253330277 hasConceptScore W4253330277C2776755627 @default.
• W4253330277 hasConceptScore W4253330277C2777938653 @default.
• W4253330277 hasConceptScore W4253330277C2778461978 @default.
• W4253330277 hasConceptScore W4253330277C2779263901 @default.
• W4253330277 hasConceptScore W4253330277C2779399171 @default.
• W4253330277 hasConceptScore W4253330277C2781413609 @default.
• W4253330277 hasConceptScore W4253330277C44249647 @default.
• W4253330277 hasConceptScore W4253330277C50382708 @default.
• W4253330277 hasConceptScore W4253330277C71924100 @default.
• W4253330277 hasIssue "21" @default.
• W4253330277 hasLocation W42533302771 @default.
• W4253330277 hasOpenAccess W4253330277 @default.
• W4253330277 hasPrimaryLocation W42533302771 @default.
• W4253330277 hasRelatedWork W12032558 @default.
• W4253330277 hasRelatedWork W12581806 @default.
• W4253330277 hasRelatedWork W13397619 @default.
• W4253330277 hasRelatedWork W14127037 @default.
• W4253330277 hasRelatedWork W14785848 @default.
• W4253330277 hasRelatedWork W1756981 @default.
• W4253330277 hasRelatedWork W18451002 @default.
• W4253330277 hasRelatedWork W3079368 @default.
• W4253330277 hasRelatedWork W3747062 @default.
• W4253330277 hasRelatedWork W7720014 @default.
• W4253330277 hasVolume "120" @default.
• W4253330277 isParatext "false" @default.
• W4253330277 isRetracted "false" @default.
• W4253330277 workType "article" @default.